LDLR Antibody (B-10): sc-373831

LDLR Antibody (B-10) is a mouse monoclonal IgG2b antibody that detects low density lipoprotein receptor (LDLR) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-LDLR antibody (B-10) plays a crucial role in understanding the function of LDLR, which is essential for mediating the uptake of low density lipoprotein (LDL) and its subsequent degradation in lysosomes, thereby providing cholesterol to cells. This process is vital for maintaining cellular cholesterol homeostasis and overall lipid metabolism. LDLR (B-10) antibody enables researchers to study the LDL receptor located on the cell surface as a transmembrane protein, where the cytoplasmic domain is critical for clustering in coated pits, facilitating rapid endocytosis of bound LDL. Dysregulation or mutations in the LDLR gene can lead to familial hypercholesterolemia, a genetic disorder characterized by elevated cholesterol levels and an increased risk of premature coronary atherosclerosis. LDLR monoclonal antibody (B-10) helps researchers gain insights into the mechanisms of cholesterol uptake and the implications of LDLR dysfunction in cardiovascular diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LDLR Antibody (B-10) References:

1. Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment.  |  Santos, PC. and Pereira, AC. 2015. Pharmacogenomics. 16: 1743-50. PMID: 26427613
2. LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity.  |  Chang, WC., et al. 2020. Endocr Relat Cancer. 27: 81-95. PMID: 31815680
3. PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis.  |  Arida, A., et al. 2021. Front Cardiovasc Med. 8: 738764. PMID: 34692791
4. LDLR missense variants disturb structural conformation and LDLR activity in T-lymphocytes of Familial hypercholesterolemia patients.  |  Barbosa, TKA., et al. 2023. Gene. 853: 147084. PMID: 36464169
5. Association of LDLR, TP53 and MMP9 Gene Polymorphisms With Atherosclerosis in a Malaysian Study Population.  |  Ahmad, Z., et al. 2023. Curr Probl Cardiol. 48: 101659. PMID: 36822563
6. Microglia contribute to cognitive decline in hypercholesterolemic LDLr-/- mice.  |  Rodrigues, MS., et al. 2024. J Neurochem. 168: 1565-1586. PMID: 37694813
7. High-Throughput Microscopy Characterization of Rare LDLR Variants.  |  Graça, R., et al. 2023. JACC Basic Transl Sci. 8: 1010-1021. PMID: 37719435
8. Wnt16 Promotes Vascular Smooth Muscle Contractile Phenotype and Function via Taz (Wwtr1) Activation in Male LDLR-/- Mice.  |  Behrmann, A., et al. 2023. Endocrinology. 165: PMID: 38123514
9. LDLR gene rearrangements in Czech FH patients likely arise from one mutational event.  |  Konečná, K., et al. 2024. Lipids Health Dis. 23: 36. PMID: 38308247
10. Exposure of Ldlr-/- Mice to a PFAS Mixture and Outcomes Related to Circulating Lipids, Bile Acid Excretion, and the Intestinal Transporter ASBT.  |  Roth, K., et al. 2024. Environ Health Perspect. 132: 87007. PMID: 39177951

The preferred LDLR antibody is LDLR Antibody (C7): sc-18823.